Xiangxue Pharmaceutical Co Ltd (300147):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Xiangxue Pharmaceutical Co Ltd (300147) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9406
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Xiangxue Pharmaceutical Co Ltd (XPH) is a pharmaceutical company that manufactures and distributes drugs and medicines. The company’s products include drugs, Chinese medicine pieces, medical instruments, health products and medicinal drinks, among others. It also provides healthcare supplements, Chinese herbal medicine and pharmaceutical medicines, among others. XPH offers services such as industrial chain services, research and development services, procurement, manufacturing, delivering services and distribution services, among others. The company provides its products and services to healthcare and medical care sectors. It has its operations in Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia, China. XPH is headquartered in Guangzhou, China.

Xiangxue Pharmaceutical Co Ltd (300147) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Xiangxue Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Xiangxue Pharma Signs Agreement with GE Medical Systems Trade & Development 12
Xiangxue Pharma Plans to Form Joint Venture in Guangzhou City 13
Licensing Agreements 14
Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 14
Equity Offering 16
Xiangxue Pharma Raises USD259 Million in Rights Offering of Shares 16
Debt Offering 17
Xiangxue Pharmaceutical Raises USD31.7 Million in Public Offering of Bonds 17
Xiangxue Pharma Raises USD75.6 Million in Public Offering of Bonds 18
Xiangxue Pharma Plans to Raise up to USD75.3 Million in Private Placement of Bonds Due 2022 19
Xiangxue Pharma Raises USD90.2 Million in Public Offering of Bonds 20
Xiangxue Pharma Plans to Raise up to USD188.5 Million in Public Offering of Bonds 21
Xiangxue Pharma Raises USD112 Million in First Tranche Public Offering of 3.39% Notes Due 2017 22
Xiangxue Pharma Announces Private Placement Of Bonds Due 2017 For US$86.1 Million 23
Xiangxue Pharma Announces Public Offering Of Corporate Bonds For Up To US$95.05 Million 24
Acquisition 25
Xiangxue Pharma Plans to Acquire Stake in a Biotechnology Firm for USD7.1 Million 25
Xiangxue Pharma to Acquire 60% Stake in Guangzhou Based Pharma Company 26
Xiangxue Pharma Plans to Acquire 55% Stake in Hubei Ji day Chinese Herbal Medicine for USD55 Million 27
Xiangxue Pharma To Acquire 70% Stake In China-Based Company For US$73.7 Million 28
Xiangxue Pharma Plans To Acquire 25% Stake In China-Based Company For US$0.03 Million 29
Xiangxue Pharma Acquires 52% Stake In China-Based Company For US$4.1 Million 30
Xiangxue Pharma Plans To Acquire 7.98% Stake In China-Based Company For US$2.4 Million 31
Xiangxue Pharmaceutical Co Ltd – Key Competitors 32
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Other Significant Developments 34
Jun 07, 2018: GE Healthcare FlexFactory Helps XPH Scale Up Industrialization of TCR T-Cell Immunotherapy Drugs 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xiangxue Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Xiangxue Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xiangxue Pharma Signs Agreement with GE Medical Systems Trade & Development 12
Xiangxue Pharma Plans to Form Joint Venture in Guangzhou City 13
Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 14
Xiangxue Pharma Raises USD259 Million in Rights Offering of Shares 16
Xiangxue Pharmaceutical Raises USD31.7 Million in Public Offering of Bonds 17
Xiangxue Pharma Raises USD75.6 Million in Public Offering of Bonds 18
Xiangxue Pharma Plans to Raise up to USD75.3 Million in Private Placement of Bonds Due 2022 19
Xiangxue Pharma Raises USD90.2 Million in Public Offering of Bonds 20
Xiangxue Pharma Plans to Raise up to USD188.5 Million in Public Offering of Bonds 21
Xiangxue Pharma Raises USD112 Million in First Tranche Public Offering of 3.39% Notes Due 2017 22
Xiangxue Pharma Announces Private Placement Of Bonds Due 2017 For US$86.1 Million 23
Xiangxue Pharma Announces Public Offering Of Corporate Bonds For Up To US$95.05 Million 24
Xiangxue Pharma Plans to Acquire Stake in a Biotechnology Firm for USD7.1 Million 25
Xiangxue Pharma to Acquire 60% Stake in Guangzhou Based Pharma Company 26
Xiangxue Pharma Plans to Acquire 55% Stake in Hubei Ji day Chinese Herbal Medicine for USD55 Million 27
Xiangxue Pharma To Acquire 70% Stake In China-Based Company For US$73.7 Million 28
Xiangxue Pharma Plans To Acquire 25% Stake In China-Based Company For US$0.03 Million 29
Xiangxue Pharma Acquires 52% Stake In China-Based Company For US$4.1 Million 30
Xiangxue Pharma Plans To Acquire 7.98% Stake In China-Based Company For US$2.4 Million 31
Xiangxue Pharmaceutical Co Ltd, Key Competitors 32
Xiangxue Pharmaceutical Co Ltd, Subsidiaries 33

List of Figures
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xiangxue Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Xiangxue Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Xiangxue Pharmaceutical Co Ltd (300147):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NuVasive Inc (NUVA):企業の製品パイプライン分析2018
    Summary NuVasive Inc (NuVasive) is a medical device company that provides minimally invasive, procedurally-integrated spine solutions. The company principally provides Maximum Access Surgery (MAS), a minimally-disruptive surgical platform. MAS platform enables surgeons to perform a range of minimall …
  • Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates:企業の戦略・SWOT・財務分析
    Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates - Strategy, SWOT and Corporate Finance Report Summary Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • SciClone Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary SciClone Pharmaceuticals Inc (SciClone), a subsidiary of Silver Biotech Investment Ltd, develops and commercializes products for the treatment of cancer, cardiovascular disorders and infectious diseases. The company’s lead product, Zadaxin (thymalfasin) is an immunostimulatory agent indicate …
  • International Personal Finance plc:企業の戦略・SWOT・財務情報
    International Personal Finance plc - Strategy, SWOT and Corporate Finance Report Summary International Personal Finance plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Beam Suntory Inc.:企業の戦略・SWOT・財務情報
    Beam Suntory Inc. - Strategy, SWOT and Corporate Finance Report Summary Beam Suntory Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • XALT Energy, LLC:電力:M&Aディール及び事業提携情報
    Summary XALT Energy, LLC (XALT Energy), formerly Dow Kokam LLC, is a provider of energy storage solutions. The company develops and manufactures energy storage solutions using Llithium- ion technology. It offers cells, packs, control systems, complete system solutions, control software and monitorin …
  • Tandem Diabetes Care Inc (TNDM):医療機器:M&Aディール及び事業提携情報
    Summary Tandem Diabetes Care Inc (Tandem) is a medical device company that designs, develops and manufactures diabetic care products. The company provides products such as t:slim X2 insulin pump, t:slim G4 insulin pump, t:flex insulin pump, t:simulator demo app, software and apps, t:connect applicat …
  • HSC Technology Group Ltd (HSC):企業の財務・戦略的SWOT分析
    HSC Technology Group Ltd (HSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Boule Diagnostics AB (BOUL):企業の財務・戦略的SWOT分析
    Summary Boule Diagnostics AB (Boule) is a medical device company that offers hematology diagnostic solutions. The company provides systems and consumer products for complete blood counts to non-institutional healthcare. It offers products such as blood cell counter and instruments, reagents, calibra …
  • Club Mediterranee SA:戦略・SWOT・企業財務分析
    Club Mediterranee SA - Strategy, SWOT and Corporate Finance Report Summary Club Mediterranee SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Alembic Pharmaceuticals Ltd (APLLTD):企業の財務・戦略的SWOT分析
    Summary Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company which manufactures and markets generic pharmaceutical products. The company’s active pharmaceutical ingredients include macrolides, NSAIDs, and other drugs. It also offers branded formulations in the areas of antibiotics and antib …
  • African Development Bank Group-エネルギー分野:企業M&A・提携分析
    Summary African Development Bank Group (AfDB) is a development finance institution. It promotes social and economic development by providing loans, grants, guarantees, equity investments and technical assistance in its regional member countries. The constituent institutions of the bank include The A …
  • Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析
    Summary Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that offers therapies. The company discovers and develops treatments for rare inherited diseases including liver and for cancers that are genetically defined. It offers RNAi technology platform GalXCTM, which is a advances …
  • Mevion Medical Systems Inc-医療機器分野:企業M&A・提携分析
    Summary Mevion Medical Systems Inc (Mevion), formerly Still River Systems is a medical equipment company that offers therapy systems. The company offers radiation therapy and proton therapy systems for the treatment of cancer. It provides MEVION S250 proton therapy system designed for preserving tre …
  • Valero Energy Corporation:企業の戦略・SWOT・財務情報
    Valero Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Valero Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Fuji Oil Holdings Inc.:戦略・SWOT・企業財務分析
    Fuji Oil Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Fuji Oil Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Monsanto Company:企業の戦略・SWOT・財務情報
    Monsanto Company - Strategy, SWOT and Corporate Finance Report Summary Monsanto Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Mediclin AG (MED):企業の財務・戦略的SWOT分析
    Summary Mediclin AG (Mediclin) is a healthcare service provider that provides rehabilitation and medical care services. The center provides services in neuro-medicine with neurology, early neurological rehabilitation, neurosurgery and neuroradiology and psychological sciences, among others. It also …
  • Detour Gold Corp:企業の戦略・SWOT・財務分析
    Detour Gold Corp - Strategy, SWOT and Corporate Finance Report Summary Detour Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Alcon Laboratories Inc:医療機器:M&Aディール及び事業提携情報
    Summary Alcon Laboratories Inc (Alcon), a division of Novartis AG, develops and manufactures devices in the field of ophthalmology. The company’s portfolio encompasses contact lenses and surgical products. Alcon’s products are used for the treatment of various conditions such as cataracts, glaucoma, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆